Compared side by side
Livagen vs ovagen: how they differ
The short answer
Both are short peptides from the Russian bioregulator program that its developers tie to the liver: livagen, four amino acids (Lys-Glu-Asp-Ala), is described as the liver’s bioregulator, and ovagen, three (Glu-Asp-Leu), is listed for the liver and the kidneys. In rat liver cells livagen raised protein synthesis, most in cells from old animals, and in rats with acute kidney injury ovagen protected kidney function better than related peptides. No human study of either has been published, and both are run in short courses rather than continuously.
Side by side
| Compared | Livagen | Ovagen |
|---|---|---|
| Category | Longevity | Longevity |
| Also known as | Lys-Glu-Asp-Ala, KEDA peptide, Lyvagen | Glu-Asp-Leu, EDL peptide |
| What it is | A four-amino-acid peptide from the Russian bioregulator program behind Epitalon, which its developers describe as a bioregulator for the liver. | A three-amino-acid peptide from the Russian bioregulator program, which its developers list for the liver and kidneys. |
| How it works | A tetrapeptide, Lys-Glu-Asp-Ala (KEDA), that Vladimir Khavinson's St. Petersburg group built from the amino acids of their liver peptide preparations and describe as the liver's bioregulator. In cultured liver cells from rats it raised protein synthesis, most in cells from old animals; given by mouth to rats for two weeks, it moved the digestive enzymes of old rats toward young levels. In lymphocytes from old people grown in the lab it loosened tightly packed chromatin, which its developers read as switching silenced genes back on, and in human serum it blocked the enzymes that break down enkephalins, the body's own opioid peptides. No human study of Livagen is indexed on PubMed. | A tripeptide, Glu-Asp-Leu (EDL), from Vladimir Khavinson's St. Petersburg bioregulator program, which its developers list for the liver and the kidneys. In rats with acute kidney injury, from the cancer drug cisplatin, the antibiotic gentamicin or a cut-off blood supply, EDL kept urine flowing, lowered protein and waste in the blood and urine and protected the kidneys' antioxidant enzymes, more strongly than the other peptides tested beside it. In the lab it binds DNA at particular sequences. No human study of Ovagen is indexed on PubMed, and its papers name it only by its sequence. |
| Commonly reported | Little to feel during a course; user reports are few. | Little to feel; user reports are few. |
| Studied range | No human study has tested a dose of Livagen: the amounts people run are their own protocol, not a reference. | No human study has tested a dose of Ovagen: the amounts people run are their own protocol, not a reference. |
| How often | Daily | Daily |
| Half-life | Unknown (never measured) | Unknown (never measured) |
| Route | SubQ injection, Oral capsules | SubQ injection, Oral capsules |
| Typical run | Run in short courses rather than continuously, like the other bioregulators: community courses run about 10–20 days, a few times a year. In the rat study it was given by mouth for two weeks. No study in people has tested a course length. | Run in courses rather than continuously, like the other bioregulators: community capsule courses run 20–30 days, repeated every few months. No study in people has tested a course length. |
| Evidence | Emerging: primarily preclinical / limited human data | Emerging: primarily preclinical / limited human data |
| Common side effects | Injection-site discomfort, mild stomach upset (capsules) | Injection-site discomfort |
- Category
- LivagenLongevity
- OvagenLongevity
- Also known as
- LivagenLys-Glu-Asp-Ala, KEDA peptide, Lyvagen
- OvagenGlu-Asp-Leu, EDL peptide
- What it is
- LivagenA four-amino-acid peptide from the Russian bioregulator program behind Epitalon, which its developers describe as a bioregulator for the liver.
- OvagenA three-amino-acid peptide from the Russian bioregulator program, which its developers list for the liver and kidneys.
- How it works
- LivagenA tetrapeptide, Lys-Glu-Asp-Ala (KEDA), that Vladimir Khavinson's St. Petersburg group built from the amino acids of their liver peptide preparations and describe as the liver's bioregulator. In cultured liver cells from rats it raised protein synthesis, most in cells from old animals; given by mouth to rats for two weeks, it moved the digestive enzymes of old rats toward young levels. In lymphocytes from old people grown in the lab it loosened tightly packed chromatin, which its developers read as switching silenced genes back on, and in human serum it blocked the enzymes that break down enkephalins, the body's own opioid peptides. No human study of Livagen is indexed on PubMed.
- OvagenA tripeptide, Glu-Asp-Leu (EDL), from Vladimir Khavinson's St. Petersburg bioregulator program, which its developers list for the liver and the kidneys. In rats with acute kidney injury, from the cancer drug cisplatin, the antibiotic gentamicin or a cut-off blood supply, EDL kept urine flowing, lowered protein and waste in the blood and urine and protected the kidneys' antioxidant enzymes, more strongly than the other peptides tested beside it. In the lab it binds DNA at particular sequences. No human study of Ovagen is indexed on PubMed, and its papers name it only by its sequence.
- Commonly reported
- LivagenLittle to feel during a course; user reports are few.
- OvagenLittle to feel; user reports are few.
- Studied range
- LivagenNo human study has tested a dose of Livagen: the amounts people run are their own protocol, not a reference.
- OvagenNo human study has tested a dose of Ovagen: the amounts people run are their own protocol, not a reference.
- How often
- LivagenDaily
- OvagenDaily
- Half-life
- LivagenUnknown (never measured)
- OvagenUnknown (never measured)
- Route
- LivagenSubQ injection, Oral capsules
- OvagenSubQ injection, Oral capsules
- Typical run
- LivagenRun in short courses rather than continuously, like the other bioregulators: community courses run about 10–20 days, a few times a year. In the rat study it was given by mouth for two weeks. No study in people has tested a course length.
- OvagenRun in courses rather than continuously, like the other bioregulators: community capsule courses run 20–30 days, repeated every few months. No study in people has tested a course length.
- Evidence
- LivagenEmerging: primarily preclinical / limited human data
- OvagenEmerging: primarily preclinical / limited human data
- Common side effects
- LivagenInjection-site discomfort, mild stomach upset (capsules)
- OvagenInjection-site discomfort
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Livagen
- Day 1–14 A quiet course
- Day 14–60 What the rat studies measured
Ovagen
- Day 1–14 A quiet course
- Day 14–60 What the rat kidney studies found
Questions people ask
How long do livagen and ovagen last?
The half-life of livagen is unknown (never measured). The half-life of ovagen is unknown (never measured).
How often are livagen and ovagen taken?
Livagen: daily. Routes: SubQ injection, oral capsules. Ovagen: daily. Routes: SubQ injection, oral capsules.
How are livagen and ovagen dosed in research?
The library carries no reference dose for livagen. No human study has tested a dose of Livagen: the amounts people run are their own protocol, not a reference. The library carries no reference dose for ovagen. No human study has tested a dose of Ovagen: the amounts people run are their own protocol, not a reference.
What are the common side effects of livagen and ovagen?
For livagen, the library lists: injection-site discomfort, mild stomach upset (capsules). For ovagen: injection-site discomfort.